Apellis raises $33M in series C

Autoimmune disease play Apellis Pharmaceuticals Inc. (Crestwood, Ky.) closed a $33 million series C round led by existing investor Morningside Ventures and new investor AJU IB Investment Co. Ltd. Epidarex Capital, another existing investor, also participated.

Apellis VP of Corporate Development David Watson said the round was tranched. The company received $7.6 million in July 2013 and $10.4 million in August, and expects to receive the final $15 million within the next few months, he said. ...